Biology of disease and clinical aspects of AIDS-associated lymphoma: a review.
AIDS-related lymphoma was not apparent until 1985, when a statistically significant increase in the frequency of lymphoma had occurred. Over 50% are high-grade lymphoma, either immunoblastic or small, noncleaved cells (Burkitt's-like lymphoma), with involvement of extranodal sites such as the central nervous system (> one-third of patients), gastrointestinal tract, skin and bone marrow. Optimal therapy for AIDS-associated lymphoma has not yet been defined. Using intensive chemotherapy protocols, high response rates, albeit of brief duration, have been demonstrated. The majority of patients succumbed to intercurrent opportunistic infections. Poor prognosis has been particularly noted in debilitated patients, patients with a CD4 cell count of < 200/dl, bone marrow and brain involvement and a history of AIDS before diagnosing the lymphoma. New strategies in the management of patients with AIDS-lymphoma should include cytotoxic therapy, antiretroviral therapy, anti-pneumocystic Carini pneumonia, prophylaxis of CNS spread and marrow protective therapy (haematopoietic growth factors).
Stein
M E
ME
Northern Israel Oncology Centre, Haifa.
Spencer
D
D
Dansey
R
R
Bezwoda
W R
WR
D017088:AIDS-Related Opportunistic Infections / Q000209:etiology* / Q000401:mortality; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002423:Cause of Death; D004359:Drug Therapy, Combination; D015497:HIV-1; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate
D000970:Antineoplastic Agents; D000998:Antiviral Agents